# Pairui Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pairui-biotech

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Latest round: Angel (Jul 3, 2024)
- Investors on record: 6

## About

Founded in 2023 and based in Suzhou, China, Pairui Biotech is a biotech company that focuses on developing innovative drugs targeting RNA modifications. In February 2025, the firm raised pre-series A funding from new investors Suzhou Xincheng Private Equity Fund Management and Oriza Holdings. Jingfang Wang, the founder of the company, once worked at Hengrui Medicine and Livzon Group.

The company's main business is to develop innovative drugs targeting RNA modifications by integrating single-molecule multi-omics experiments and artificial intelligence-based computational simulations. It also develops drug molecules for immune and inflammation-related diseases.

The company’s revenue is generated by providing innovative drugs targeting RNA modifications.

## Funding rounds

- Angel, Jul 3, 2024 — Soochow Venture Investment, Laurel Venture, Zhuhai Hengqin Kangju Private Equity Fund Management Co., Ltd., Choice Capital
- Angel, Sep 15, 2023 — Soochow Venture Investment, Ming Bioventures, Zhidao Capital

## Investors

- Soochow Venture Investment (https://capitalatlas.ai/funds/soochow-venture-investment) — Angel
- Ming Bioventures (https://capitalatlas.ai/funds/ming-bioventures) — Angel
- Zhidao Capital (https://capitalatlas.ai/funds/zhidao-capital) — Angel
- Laurel Venture (https://capitalatlas.ai/funds/laurel-venture) — Angel
- Zhuhai Hengqin Kangju Private Equity Fund Management Co., Ltd. — Angel
- Choice Capital (https://capitalatlas.ai/funds/choice-capital) — Angel